Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
David Liew drdavidliew
3 years 1 month ago
Question is: does early stage PNL protect vs vascular remodelling in GCA? What about TCZ?
Salvarini group:
18 new GCA pts
GUSTO Rx (TCZ +IVMPx3, no ongoing PNL)
PET/CT: 0, 24, 52w
inflamm controlled but aortic diltation
plausible concerns reinforced!
ABST0480 #ACR22 @RheumNow https://t.co/Wnw4oxaZn7
Janet Pope Janetbirdope
3 years 1 month ago
RECITAL trial #CTD with #ILD RCT of #rituximab vs #cyclophosphamide showed value overall with each Rx. Only 6 months as then maybe you would retreat w rituximab? Not superior on lungs but in #scleroderma-skin improvement better w RTX. #ACRBest #ACR22 @RheumNow abst#3 Impt for Rx https://t.co/lX1YPsr5U6
Mike Putman EBRheum
3 years 1 month ago
I implemented a Fast Track GCA clinic at my hospital (>60 encounters now!)
I have have begun to think the main benefit is ACCESS
Ultrasound is great and I do them, but I recommend starting one REGARDLESS of whether or not you do ultrasound
#ACR22 @RheumNow #0463 https://t.co/4uuotmNnoi
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR2022 Abstr#0003. Subgroup analysis from RECITAL RCT Rituximab vs Cyclophosphamide in CTD-ILD showed both therapies improved FVC in Myositis and MCTD but not Scleroderma. To interpret with caution (non-powered). Key message: To consider RTX as option for CTD-ILD @RheumNow https://t.co/NhJKXRdw7q
Olga Petryna DrPetryna
3 years 1 month ago
#acr22 #abst0003 @RheumNow RECITAL: RTX vs CYC for CTD related ILD:comparable in MCTD, CYC better for myositis related ILD. Both stabilize but not improve FVC in SSc ILD. In SSc RTX but not CYC improved skin thickness by mRss at 24 wks. better safety of RTX vs CYC #acrbest https://t.co/6Hry5hy1SS
Catherine Sims, MD DrCassySims
3 years 1 month ago
What were the most common adverse events in @pfizer funded Xeljanz for AS?
💩diarrhea
😴fatigue
🧠headache
🫀hypertension
📍weight gain
#ACR22 @RheumNow
David Liew drdavidliew
3 years 1 month ago
@vitortexas @RheumNow Observational data, no doubt some channelling! This data is not definitive, but highlights serious questions.
Our practices need to be challenged - IVMP has questionable biological plausibility, never had clear benefit, but has clear harm.
Thanks for the comment! #ACR22
Aurelie Najm AurelieRheumo
3 years 1 month ago
Association between RA and coeliac disease: CD pts = 57% higher risk of RA vs. matched non-CD pts. Risk associated w/ age aOR 2, female aOR 2.6, socioeconomic status aOR 1.2, Medicaid aOR : 1.3.
https://t.co/APdWW7f1U6
Abst #0271 #ACR22 @Rheumnow https://t.co/djriO3QMAh
Julian Segan JulianSegan
3 years 1 month ago
Neural networks can delineate different forms of inflammatory arthritis (sero+, sero- & PsA) based on structural/inflammation patterns on MRI. Required use of contrast enhancement.
Are we going to be obsolete soon @DrCMcMaster?
@RheumNow ABSR0242 #ACR22
https://t.co/JExk9HiIYu https://t.co/G2tCafE8A7
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0004 Macrophage Activation Syndrome is associated with Systemic JIA #arthritis but how do they link up? Mice studies show mTORC1 is a key driver. Studies needed to assess mTORC1-inhibitor e.g. rapamycin, sirolimus etc. for SJIA-related MAS @RheumNow https://t.co/sH9seK1n8u
Bella Mehta bella_mehta
3 years 1 month ago
Why are #sJIA pts prone to #MAS?
Potential new treatment target mTORC1?
mTORC1 gene signature in monocytes
Mice models and human translational studies with evidence
#ACRBest #ACR22 @rheumnow abst#0004 #stillsdisease #autoinflammatorydisease https://t.co/Q2ehfyWMKG
Julian Segan JulianSegan
3 years 1 month ago
Safety data from 9 phase 3 UPA trials (RA, PsA & AS). In 11,271 pt-yrs exposure, no increased signal for cancer (excluding NMSC) cf. ADA/MTX. NMSC was higher however.
What data (if any) would reassure people in this space?
@RheumNow ABST0292 #ACR22
https://t.co/tS5r66loqP
Aurelie Najm AurelieRheumo
3 years 1 month ago
MIRROR RCT: Pegloticase + MTX 60% response rate vs. 30% Pegloticase + PBO in uncontrolled gout patients. 1/2 patients w/ resolution of >= 1tophus in MTX gpe vs. < 1/3 in PBO. Safety profile comparable between groups.
https://t.co/oJ6kYw94L3 Abst#0001 #ACR22 @Rheumnow https://t.co/Hmeym3Cy7n
David Liew drdavidliew
3 years 1 month ago
Beautiful translational work looking at mTORC1 driving systemic JIA to MAS - a deadly escalation.
An already accessible target:
Rapamycin in sJIA a serious proposition!
ABST0004 @BostonChildrens #ACR22 @RheumNow https://t.co/fW3C5ludjc
Aurelie Najm AurelieRheumo
3 years 1 month ago
RECITAL trial: First line RTX vs. CYC in ILD 🫁 asso w/ SSc, mixed CTD or Myositis.
Primart endpoint FVC 24 wks improved in both mCTD and Myositis associated ILD but only stabilized in SSc-ILD. RTX improved skin thickness 24 wks. https://t.co/MQcqds0jYA
Abst#0003 #ACR22 @Rheumnow https://t.co/pK48716nIg
Poster Hall